This suggests AML utilizes GFAT1 as the rate limiting enzyme for the HBP, unlike other cancers such as ovarian cancer (40, 65) and lung cancer (66), where GFAT2 appears to predominately drive the HBP. This evidence concerns the gene GFPT1 and lung carcinoma.